A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-05

Study Completion Date

2019-01-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bullous pemphigoid (BP) is a chronic, inflammatory, subepidermal, autoimmune blistering disease which mainly develops in the elderly, with onset usually in the late 70s and a substantial increase in incidence in people older than 80 years. If untreated, it can persist for months or years, with periods of spontaneous remissions and exacerbations. It has been found that blisters and sera of BP patients contain abnormally high levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and IL-8. Recently, it also has been demonstrated that NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome components (the NLRP3-caspase-1-IL-18 axis) were significantly up-regulated in peripheral blood mononuclear cells from BP patients and positively correlated with disease activity. AC-203 is a topical formulation of an oral modulator of inflammasome and IL-1beta pathways. In vitro studies have demonstrated that AC-203 significantly reduced secretion of IL-6 and moderately reduced IL-8 secretion in HaCaT cells treated with specific anti-BP180 IgG. This study is designed to test the safety, tolerability, efficacy, and pharmacokinetics of AC-203 ointment (vs. a topical steroid comparator representing standard of care) ointment in subjects with BP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

NCT03468322

Inherited Epidermolysis Bullosa

COMPLETED PHASE2

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132

Generalized Epidermolysis Bullosa Simplex

RECRUITING PHASE2/PHASE3

A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne

NCT03709654

Acne Vulgaris

COMPLETED PHASE1

Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands

NCT06026358

Actinic Keratoses

WITHDRAWN PHASE4

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

NCT02832063

Acne Vulgaris

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bullous Pemphigoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AC-203

Group Type EXPERIMENTAL

AC-203 1% Topical Ointment

Intervention Type DRUG

AC-203 1% ointment BID (twice daily)

Clobetasol

Group Type ACTIVE_COMPARATOR

Clobetasol 0.05% Topical Ointment

Intervention Type DRUG

Clobetasol 0.05% Topical Ointment BID

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AC-203 1% Topical Ointment

AC-203 1% ointment BID (twice daily)

Intervention Type DRUG

Clobetasol 0.05% Topical Ointment

Clobetasol 0.05% Topical Ointment BID

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 20 to 90 years old, inclusive, at enrollment.
2. Diagnosis of bullous pemphigoid confirmed by histopathology and one of following assessments:

1. Direct immunoﬂuorescence (DIF)
2. Indirect immunoﬂuorescence (IIF)
3. ELISA test (ELISA detection of immunoglobulin G (IgG) anti-BP180 autoantibodies in serum more than 9 U/mL).
3. Localized or limited BP with the occurrence of \<10 new blisters per day in the week prior to enrollment.
4. Is male, or is female and meets all the following criteria:

1. Not breastfeeding
2. If of childbearing potential (defined as non-post hysterectomy or non-post-menopausal \[≥50 years of age and amenorrheic for at least 1 year\]), must have a negative pregnancy test result (human chorionic gonadotropin, beta subunit \[bhCG\]) at Visit 1, and must practice and be willing to continue to practice appropriate birth control (abstinence, double barrier methods, hormonal contraceptives, intrauterine device, or tubal ligation) during the entire duration of the study
5. Is able to understand and sign the Informed Consent Form (ICF), communicate with the investigator, and understand and comply with protocol requirements.

Exclusion Criteria

1. Diagnosis of pemphigus, dermatitis, eczema, psoriasis, or other skin condition which in the opinion of the investigator may confound diagnosis, treatment, or evaluation of bullous pemphigoid.
2. Use of oral steroids in the 2 weeks prior to enrollment at a dose greater than prednisolone equivalent dose (PED) of 10 mg/day.
3. Use of topical steroids for more than 3 consecutive days in the 2 weeks prior to enrollment.
4. Use of non-steroid immunosuppressants including but not limited to azathioprine, mycophenolate, cyclophosphamide, chlorambucil, methotrexate, tacrolimus, or cyclosporine in the 2 weeks prior to enrollment.
5. Use of systemic antibiotics in the 2 weeks prior to enrollment.
6. Use of oral dapsone in the 2 weeks prior to enrollment.
7. Treatment with intravenous immunoglobulin (IVIG) in the 8 weeks prior to enrollment.
8. Any prior use of approved or investigational biologic anti-inflammatory therapy within 6 months prior to enrollment, including but not limited to: anakinra, rilonacept, canakinumab, etanercept, adalimumab, infliximab, rituximab, certolizumab, golimumab, tocilizumab, bertilimumab, or abatacept.
9. Presence of active systemic infections.
10. Any clinically significant medical condition or laboratory value that could potentially affect study participation and/or personal well-being, as judged by the investigator.
11. History of allergy or hypersensitivity to any component of study medication or clobetasol.
12. Has participated in a clinical study within 30 days prior to enrollment.
13. Is an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the clinical study site, or is directly affiliated with the study at the clinical study site.
14. Is employed by the sponsor (i.e., is an employee, temporary contract worker, or designee responsible for the conduct of the study).

Minimum Eligible Age

20 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No